RecruitingPhase 2NCT05090891
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
Studying Fibrodysplasia ossificans progressiva
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Incyte Corporation
- Principal Investigator
- Amanda McBride, MDIncyte Corporation
- Intervention
- INCB000928(drug)
- Enrollment
- 98 enrolled
- Eligibility
- 2-99 years · All sexes
- Timeline
- 2022 – 2033
Study locations (27)
- University of California San Francisco Medical Center, San Francisco, California, United States
- Mayo Clinic Rochester, Rochester, Minnesota, United States
- Children'S Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Penn Medicine - Perelman Center For Advanced Medicine, Philadelphia, Pennsylvania, United States
- Hospital Italiano de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina
- Royal North Shore Hospital, St Leonards, New South Wales, Australia
- Murdoch Children'S Research Institute, Parkville, Victoria, Australia
- Albert Einstein Israelite Hospital, São Paulo, Brazil
- University Health Network Toronto General Hospital, Toronto, Ontario, Canada
- Centro de Estudios Reumatologicos, Santiago, Chile
- Beijing Childrens Hospital Capital Medical University, Beijing, China
- Tongji Hospital of Tongji University, Shanghai, China
- Shanghai Childrens Medical Center, Shanghai, China
- Childrens Hospital of Fudan University, Shanghai, China
- Ap-Hp Hopital Lariboisiere, Paris, France
- +12 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05090891 on ClinicalTrials.govOther trials for Fibrodysplasia ossificans progressiva
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06724562IL1 Inhibition in FOPUniversity of California, San Francisco
- RECRUITINGNCT06089616A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)Ipsen
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT06508021A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)Ashibio Inc
- ACTIVE NOT RECRUITINGPHASE3NCT05394116A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)Regeneron Pharmaceuticals
- RECRUITINGNCT02745158The Fibrodysplasia Ossificans Progressiva (FOP) Connection RegistryThe International FOP Association